List of Excipients in Branded Drug MENEST

« Back to Dashboard

Generic Drugs Containing MENEST

Company	Ingredient	NDC	Excipient
Physicians Total Care Inc	estrogens, esterified	54868-6211	D&C YELLOW NO. 10
Physicians Total Care Inc	estrogens, esterified	54868-6211	ETHYLCELLULOSES
Physicians Total Care Inc	estrogens, esterified	54868-6211	FD&C YELLOW NO. 6
Physicians Total Care Inc	estrogens, esterified	54868-6211	HYDROXYPROPYL CELLULOSE
Physicians Total Care Inc	estrogens, esterified	54868-6211	HYPROMELLOSE 2910
Physicians Total Care Inc	estrogens, esterified	54868-6211	LACTOSE

What are the Most Frequently-Used Excipients in MENEST?

# Of NDCs	Excipient
2	D&C YELLOW NO. 10
1	ETHYLCELLULOSE
1	ETHYLCELLULOSES
2	FD&C YELLOW NO. 6
2	HYDROXYPROPYL CELLULOSE
2	HYPROMELLOSE 2910

MENEST Excipient Strategy and Commercial Opportunities in Esterified Estrogens Tablets

Last updated: October 7, 2026

Menest is an oral tablet containing esterified estrogens, primarily sodium estrone sulfate and sodium equilin sulfate. Its commercial opportunity is driven less by conventional patent exclusivity than by formulation reliability, supply continuity, regulatory execution, and differentiation in menopausal hormone therapy. The strongest near-term strategies are generic or authorized-generic development, excipient-led manufacturing improvements, and adjacent estrogen products using comparable oral-tablet technology.

What is Menest and what excipient system does it use?

Menest is an immediate-release oral tablet indicated for estrogen-responsive conditions, including moderate-to-severe vasomotor symptoms associated with menopause and vulvar or vaginal atrophy. The product is available in multiple strengths, historically including 0.3 mg, 0.625 mg, 1.25 mg, and 2.5 mg esterified estrogens tablets.[1]

Esterified estrogens are not a single chemically defined estrogen. The drug substance is a mixture of estrogen sulfate esters. That composition affects dissolution, assay strategy, impurity control, and raw-material sourcing.

Product attribute	Menest profile
Active ingredient	Esterified estrogens
Principal estrogen components	Sodium estrone sulfate and sodium equilin sulfate
Dosage form	Immediate-release tablet
Route	Oral
Regulatory pathway for competitors	Likely ANDA for pharmaceutical equivalents; 505(b)(2) for materially different formulations or indications
Primary formulation challenge	Uniformity and dissolution of a low-dose, estrogenic sulfate-ester mixture
Main commercial risks	Active-ingredient supply, dose proportionality, manufacturing scale, labeling and safety requirements
Primary excipient opportunity	Robust tablet manufacture with low variability across strengths

The excipient system must support content uniformity at low doses, protect the active mixture from segregation, provide adequate mechanical strength, and deliver prompt dissolution. Standard direct-compression or wet-granulation platforms may be suitable, but the optimal process depends on particle size, bulk density, moisture sensitivity, and the physical form of the esterified-estrogen drug substance.

What excipients are important for Menest tablets?

The relevant excipient classes are diluents, binders, disintegrants, lubricants, glidants, and film-coating materials. Historical Menest labeling identifies conventional tablet excipients, but the exact composition can vary by manufacturer, strength, and product version. The current reference and proposed product labels should control any development or equivalence assessment.[1,2]

Diluents

Lactose, microcrystalline cellulose, dibasic calcium phosphate, and starch-based diluents are potential candidates.

Lactose can provide favorable flow and compressibility but creates a labeling issue for patients with specific intolerance concerns. Microcrystalline cellulose supports direct compression and can reduce dependence on wet granulation. Dibasic calcium phosphate can improve tablet hardness but may alter disintegration and dissolution if used at high concentrations.

The best commercial choice is usually the excipient that produces consistent content uniformity across all strengths while maintaining a common manufacturing process. A single platform for 0.3 mg through 2.5 mg tablets reduces validation and inventory costs.

Binders

Povidone, pregelatinized starch, hydroxypropyl cellulose, and related binders can improve granule strength. Excessive binder concentration can slow disintegration and dissolution, particularly in a low-dose immediate-release tablet.

A formulation developer should prioritize a low-binder system when the drug substance has adequate compactibility. If wet granulation is required, the process should be designed to control granule size and prevent preferential distribution of the estrogen sulfate mixture.

Disintegrants

Croscarmellose sodium, sodium starch glycolate, and crospovidone are standard options. The selection should be based on dissolution performance, tablet hardness, and sensitivity to compression force.

Crospovidone can support rapid disintegration without substantial swelling. Sodium starch glycolate can provide strong disintegration but may be sensitive to over-granulation or excessive compression. Croscarmellose sodium is widely used in immediate-release products but can interact with formulation moisture and processing conditions.

Lubricants and glidants

Magnesium stearate is a conventional lubricant. Over-lubrication can create a hydrophobic tablet surface and delay dissolution. Colloidal silicon dioxide can improve flow when the drug substance or blend has poor handling characteristics.

For Menest, lubricant optimization is commercially important because small process changes can create dissolution differences between strengths. A formulation that depends on a narrow lubrication window may increase manufacturing failure risk.

Film-coating materials

Film coating can improve appearance, strength, swallowability, and product identification. Common systems use hypromellose, polyethylene glycol, titanium dioxide, and permitted colorants.

Color coding by strength has a practical value in estrogen products because dosing errors have clinical consequences. A coating system should maintain tablet identification without introducing dissolution variability or unnecessary supply-chain complexity.

What excipient strategy is best for a generic Menest product?

A generic developer should prioritize a common, scalable immediate-release platform rather than pursue a novel excipient system without a regulatory need.

The preferred development sequence is:

1. Characterize the reference product across all marketed strengths.
2. Establish the particle-size, density, moisture, and flow profile of the esterified-estrogen drug substance.
3. Select a common diluent and disintegrant platform.
4. Demonstrate content uniformity through blend and tablet sampling studies.
5. Optimize compression and lubrication to match dissolution.
6. Confirm stability under long-term and accelerated conditions.
7. Establish bioequivalence using the applicable FDA product-specific expectations.

Direct compression versus wet granulation

Criterion	Direct compression	Wet granulation
Process complexity	Lower	Higher
Capital requirement	Lower	Higher
Risk of segregation	Potentially higher	Often lower after granule formation
Moisture exposure	Lower	Higher
Content uniformity	Depends heavily on blend properties	Can improve if granulation is controlled
Scale-up	Generally simpler	Requires tighter process control
Best use case	Good-flowing, compatible drug substance	Poor-flowing or segregation-prone drug substance

Direct compression offers the strongest cost position if the active mixture can be distributed uniformly at low concentration. Wet granulation may be preferable if the drug substance has poor flow or if the dose is too low to achieve robust blend uniformity.

A hybrid approach is also possible. Drug-layered granules or an ordered-mixture process can improve low-dose distribution while avoiding extensive wet processing.

What FDA regulatory pathway applies to Menest competitors?

A conventional generic Menest tablet would normally be evaluated under an abbreviated new drug application, provided the applicant can demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug.

Key ANDA requirements include:

• Same active ingredient.
• Same dosage form and route of administration.
• Same strength or strengths.
• Comparable labeling, subject to permitted generic changes.
• Pharmaceutical equivalence.
• Bioequivalence.
• Compliance with current good manufacturing practice.
• Adequate controls for identity, strength, quality, purity, and stability.

A 505(b)(2) application may be relevant if a company proposes a materially different dosage form, modified-release product, new route, different dosing regimen, or additional clinical use. That pathway may support differentiated products but normally carries higher clinical and regulatory costs.

The FDA Inactive Ingredient Database can support excipient selection, but prior use in an approved product does not eliminate the need to establish suitability in the proposed formulation.[3]

What patents protect Menest?

Menest is a legacy oral estrogen product. Its principal commercial protection is unlikely to depend on a broad, active patent estate covering the basic esterified-estrogen tablet. The relevant competitive analysis should separate three categories:

Protection category	Menest relevance
Active-ingredient composition patents	Limited for a legacy esterified-estrogen mixture
Formulation patents	Potentially relevant if an individual manufacturer has claimed a specific tablet, coating, or release profile
Method-of-use patents	Potentially relevant for particular estrogen indications or dosing regimens
Regulatory exclusivity	Likely limited for a mature product
Trade secrets	Potentially important for sourcing, blending, and manufacturing controls

Patent status should be checked in the FDA Orange Book, USPTO Patent Center, and relevant court records. The Orange Book is the controlling source for patents and exclusivity listed against an approved NDA, while USPTO records establish prosecution and expiration information.[4,5]

No commercial strategy should assume that historical Menest branding creates meaningful blocking rights. For a generic manufacturer, the primary risks are likely to be regulatory equivalence, active-ingredient sourcing, product availability, and manufacturing execution rather than a large formulation patent thicket.

When does Menest lose exclusivity?

Menest’s commercial exclusivity is principally a legacy issue. A mature oral tablet containing esterified estrogens is generally exposed to generic competition once applicable regulatory exclusivity and enforceable listed patents have expired or no longer block approval.

The relevant dates are:

Milestone	Commercial implication
Original NDA approval	Establishes the reference product and regulatory history
Pediatric exclusivity, if granted	Adds six months to applicable exclusivity
Listed patent expiration	May delay approval or launch of an ANDA
ANDA approval	Permits a generic launch subject to patent certifications and litigation
Product discontinuation	Does not necessarily eliminate reference-product status
Current market availability	Determines substitution and commercial viability

A product can remain FDA-approved while being commercially unavailable. That distinction matters because an approved reference product may continue to support generic development even when the branded product has limited sales.

What Paragraph IV challenges could affect Menest?

A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. If Menest has no currently enforceable Orange Book-listed patents, a generic applicant may use a different certification pathway. If listed patents exist, a Paragraph IV filing can trigger patent litigation and potentially a 30-month stay under the Hatch-Waxman framework, subject to statutory conditions.[6]

The practical litigation scenarios are:

1. The applicant files an ANDA with a Paragraph IV certification.
2. The patent holder sues within the statutory period.
3. FDA approval may be stayed for up to 30 months unless the litigation resolves earlier or the court issues a decision.
4. The parties may settle, allowing a negotiated launch date.
5. The generic may enter after a judgment of invalidity, non-infringement, unenforceability, or expiration.

Because Menest is a mature product, a new entrant should evaluate whether any listed patent has enough remaining life to justify litigation. Short remaining patent life can make a Paragraph IV case economically unattractive even when the legal position is credible.

What formulation patents could create commercial barriers?

Formulation patents could cover:

• Specific ratios of esterified-estrogen components.
• Particle-size distributions.
• Tablet excipient combinations.
• Granulation methods.
• Film coatings.
• Dissolution profiles.
• Stabilization systems.
• Packaging configurations.
• Dose-specific tablet architecture.

A formulation patent is strongest when it claims a technically necessary feature that is difficult to design around and can be tied to measurable product performance. A claim covering a narrow excipient ratio may be avoidable if a competitor can use a different diluent, disintegrant, or manufacturing process without losing bioequivalence.

For Menest, formulation patents would be more commercially relevant if they cover a differentiated product, such as a rapid-disintegration tablet, lower-dose tablet, orally disintegrating tablet, or combination estrogen-progestin product. Such products may require 505(b)(2) development rather than a simple ANDA.

What commercial opportunities exist for Menest excipients?

Generic tablet supply

The clearest opportunity is supplying excipients and manufacturing services to a generic Menest applicant. Potential value lies in:

• Low-dose content-uniformity performance.
• Common platform manufacture across multiple strengths.
• Reduced compression-force sensitivity.
• Rapid dissolution.
• Low dusting and improved operator safety.
• Reliable global supply.
• Compatibility with high-speed tablet presses.

Excipient vendors can create competitive differentiation through co-processed excipients designed for direct compression and low-dose blend uniformity.

Authorized generic or contract manufacturing

An authorized generic strategy could use the existing Menest formulation or a closely related formulation under a commercial agreement with the NDA holder or distributor. This approach may reduce brand erosion risk while expanding channel access.

Contract manufacturers can compete on batch size flexibility, regulatory documentation, serialization, and the ability to manufacture several strengths using a common process.

Reformulated oral estrogen products

A company could use Menest as a platform for:

• Lower-dose tablets.
• Improved swallowability.
• Orally disintegrating tablets.
• Scored tablets.
• Combination estrogen-progestin products.
• Calendar blister packaging.
• Unit-dose adherence packaging.

Each product requires a separate assessment of regulatory pathway, clinical requirements, and patentability.

Excipient and process intellectual property

The most defensible IP may concern the manufacturing process rather than a basic excipient list. Potential claims could cover:

• A controlled blending sequence.
• Granule formation conditions.
• A low-shear process that maintains component distribution.
• A tablet with defined disintegration and dissolution parameters.
• A stabilized esterified-estrogen composition.
• A packaging system that limits moisture or light exposure.

Process patents can create value if they reduce failed batches, improve scale-up, or permit a lower-cost manufacturing route. Their enforcement is more difficult when the process occurs inside a competitor’s facility, so the commercial value depends on whether the resulting product can be analytically distinguished.

How does Menest compare with other menopausal estrogen products?

Product category	Active ingredient	Dosage forms	Main competitive advantage
Menest	Esterified estrogens	Oral tablets	Established oral estrogen mixture
Conjugated estrogens	Multiple estrogen conjugates	Oral tablets, vaginal products	Strong reference-product recognition
Micronized estradiol	Estradiol	Oral tablets, transdermal, vaginal	Broad route and formulation options
Estradiol patches	Estradiol	Transdermal systems	Avoids first-pass hepatic exposure
Vaginal estrogen products	Estradiol or other estrogens	Creams, tablets, rings	Local therapy and lower systemic exposure
Estrogen-progestin combinations	Estrogen plus progestin	Oral and transdermal products	Addresses endometrial protection in appropriate patients

Menest’s main disadvantage is route concentration. Oral products face competition from transdermal and local estrogen systems, which provide alternative exposure profiles and patient preferences. A Menest-based commercial strategy therefore benefits from price, availability, dosage flexibility, and manufacturing efficiency rather than relying only on brand familiarity.

What biosimilar risks apply to Menest?

Biosimilar risk is not directly applicable. Menest is a small-molecule drug product, not a biologic. Competitors would generally enter through the ANDA pathway or, for materially different products, through 505(b)(2). The relevant substitution risk comes from generic esterified-estrogen tablets, estradiol products, conjugated-estrogen products, and other menopausal hormone therapies.

What regulatory and safety issues affect excipient selection?

Estrogen products require careful control of potency, impurities, stability, and labeling. Excipients should be selected with attention to:

• FDA maximum daily exposure by route.
• Prior use in oral solid dosage forms.
• Allergen and intolerance labeling.
• Nitrosamine and elemental-impurity risk where relevant.
• Residual solvents.
• Microbial control for botanical or animal-derived materials.
• Supply-chain traceability.
• Compatibility with packaging.
• Consistency across commercial strengths.

Animal-derived or variable-origin materials may create sourcing and regulatory concerns. A synthetic, compendial, and globally available excipient system generally offers better long-term commercial resilience.

What generic launch scenarios exist for Menest?

Low-cost multisource launch

A manufacturer launches a conventional immediate-release tablet in the highest-demand strengths. The strategy depends on low manufacturing cost, a reliable active-ingredient supplier, and pharmacy-channel access.

Premium generic launch

A company launches a formulation with improved tablet identification, scoring, packaging, or dose flexibility. The product may command limited pricing differentiation but can compete where supply reliability is poor.

505(b)(2) differentiated launch

A company develops a new delivery system, lower-dose product, or combination therapy. This strategy has greater development cost but may provide stronger lifecycle protection.

Supply-constrained opportunity

A manufacturer targets the product during periods of shortage or limited availability. FDA shortage records, NDC activity, and wholesaler data should be monitored because a low-volume legacy drug can still have attractive margins when supply is unreliable.[7]

What geographic coverage matters for Menest?

The United States is the most relevant market for Orange Book and Hatch-Waxman analysis. European and other markets may classify esterified-estrogen products differently and may not use the same reference product, patent listing, or substitution framework.

A global excipient strategy should address:

• FDA inactive-ingredient acceptance.
• European Pharmacopoeia and United States Pharmacopeia compliance.
• Regional colorant restrictions.
• Country-specific labeling.
• Local bioequivalence requirements.
• Import and supply continuity.
• Manufacturing-site registration.
• Pediatric and pharmacovigilance obligations.

A formulation that uses globally restricted colorants or regionally uncommon excipients can increase product complexity. A colorant-free or globally standardized coating platform may reduce regulatory variation.

How strong is the Menest patent estate?

The estate appears commercially weaker than the patent estates surrounding newer drugs, extended-release products, transdermal systems, and combination hormone therapies. The principal barriers are more likely to be technical and operational:

• Maintaining uniformity across low-dose strengths.
• Procuring consistent esterified-estrogen drug substance.
• Matching dissolution and bioequivalence.
• Managing multiple tablet strengths.
• Securing sufficient commercial volume.
• Maintaining stable distribution.

The most attractive IP opportunity is a differentiated formulation or process that produces measurable performance improvements and supports a distinct regulatory filing. A basic excipient substitution is less likely to create durable exclusivity.

Key Takeaways

• Menest is an oral immediate-release esterified-estrogen tablet and a mature small-molecule product.
• The strongest excipient strategy uses a scalable common platform across strengths.
• Content uniformity, dissolution, lubrication, and active-ingredient sourcing are the principal technical issues.
• Generic entry would generally proceed through an ANDA if pharmaceutical equivalence can be established.
• Biosimilar competition is not relevant; generic and 505(b)(2) competition is.
• Formulation patents may matter, but legacy Menest competition is more likely to be shaped by manufacturing and supply economics.
• The best commercial opportunities are generic manufacture, co-processed excipient supply, authorized-generic arrangements, and differentiated oral estrogen products.
• Current Orange Book, FDA label, NDC, and litigation records should govern any launch-date or patent-clearance decision.

FAQs

Is Menest a biologic or a small-molecule drug?

Menest is a small-molecule estrogen product containing esterified estrogen sulfate components. It is not eligible for biosimilar competition.

Can a company make a generic Menest tablet with different excipients?

Yes, subject to FDA requirements for pharmaceutical equivalence, bioequivalence, quality, labeling, and inactive-ingredient acceptability. Different excipients must not alter the product’s performance or safety profile.

Is lactose a commercial concern in Menest formulation development?

It can be. Lactose may be suitable for an oral tablet, but developers must assess patient labeling, supplier consistency, moisture behavior, and compatibility with the selected manufacturing process.

Would an orally disintegrating Menest product qualify as an ANDA?

Not necessarily. A materially different dosage form may require a 505(b)(2) application unless FDA determines that the proposed product can be supported through the ANDA pathway.

What is the largest non-patent barrier to a Menest generic?

Reliable supply of a consistent esterified-estrogen drug substance combined with low-dose content uniformity and dissolution control is likely to be the principal barrier.

References

1. DailyMed. (n.d.). Menest: Esterified estrogens tablet, prescribing information. U.S. National Library of Medicine.

2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

5. United States Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov/

6. U.S. Food and Drug Administration. (n.d.). Hatch-Waxman Amendments and abbreviated new drug applications. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda

7. U.S. Food and Drug Administration. (n.d.). Drug shortages. https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages